AI & Bioscience w/ Miles Harrison (CEO of Conexeu), SK Hynix IPO & Blue Origin Fundraise

9 Jul 2026 · 49 min · 17 chapters

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

How AI is accelerating biotech discovery (but not clinical/regulatory validation), and how GLP-1 weight-loss is creating a new aesthetic/tissue-regeneration market; plus market headlines on Iran ceasefire escalation, SK Hynix’s AI-memory IPO, and a U.S. Treasury draft warning about an AI bubble.

Guest backgrounds

Miles Harrison is CEO of ConnectSUE (ticker CNXU), recently listed on NASDAQ. He previously led Galderma’s North American business, scaling Cetaphil from $1.2B to $2.1B revenue, and co-founded an aesthetics company sold in an eight-figure exit. He sits on Castle Biosciences’ board.

Key claims

AI can “close the gap” on biology’s data bottleneck and speed discovery (3–4 years vs 10–12), but patient safety/efficacy timelines can’t be compressed. GLP-1s create downstream patients needing longer-lasting volumization; ConnectSUE’s extracellular matrix hydrogel/collagen aims to regenerate tissue rather than just add temporary volume.

Notable examples

1 in 8 U.S. adults on GLP-1; 63% seek aesthetic care. ConnectSUE plans a 510(k) via wound care first, then expands to aesthetics/dental/breast reconstruction.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Chapters

Tap a time to open that second in VO

Intersection of AI and Biotechnology

0:04 to 0:27

Discussion about AI's impact on biotech and drug discovery.

“It can help you with practically anything on the web, like restoring a vintage motorcycle from a 50-page restoration block, or finally break down that long article you've had open for weeks.”

Intersection of AI and Biotechnology

2:06 to 4:11

Discussion about AI's impact on biotech and drug discovery.

“All right, everyone, so before we jump to our radar points for this week's episode, we've got a guest joining us that I've been really excited about.”

The Role of AI in Accelerating Healthcare Innovation

4:11 to 6:13

Exploration of how AI is changing healthcare innovation cycles.

“This has been a big topic for Austin and I for quite some time.”

Clinical Validation and AI Limitations

6:13 to 7:30

Insights on the balance between AI speed and patient safety.

“So I think that's where we will win speed and getting around all of that data, which is quite significant for biology.”

Potential of AI in Healthcare Market Growth

7:30 to 10:16

Discussion on AI's role in creating future trillion-dollar healthcare companies.

“So, you know, you can't simulate your way to a 510k clearance, for example, or a pre-marketing authorization, a PMA approval, and you wouldn't want to.”

GLP-1s and the New Aesthetic Medicine Market

10:16 to 14:01

Analysis of how GLP-1s are shaping a new patient demographic in aesthetics.

“where AI lets healthcare innovation move at a fraction of software speed, but the ceiling is enormous.”

Regenerative Tissue Opportunities in Aesthetics

14:01 to 18:18

Learn about the potential of ECM-based regenerative tissue approaches in enhancing aesthetic treatments.

“I think regenerative tissue opportunities like ECM-based approaches we have will be the next category, and they will work the same way that biostimulators did back in the day and neuromodulators once did.”

Connection's CXU Platform and Future Vision

18:19 to 23:10

Explore the multifunctional aspects of Connection's CXU platform and its implications for future products.

“So this is gonna be great for our audience because this is such a big sector.”

Personal Health Journey and Longevity Insights

23:11 to 23:40

Discuss personal health strategies and the exciting potential of longevity through biotech advancements.

“And that's what we're going to see across many of these other verticals that we're talking about.”

Geopolitical Risks and Market Impacts

24:16 to 28:00

Analyze the implications of geopolitical tensions on oil prices and the broader market.

“Well, let's talk through the chain of events.”
Show all 17 chapters

SK Hynix IPO Insights

28:00 to 34:44

Learn about SK Hynix's critical role in the AI supply chain and its upcoming IPO.

“So, you know, about$50 billion short, but still pretty big if you ask me.”

AI Bubble Concerns

34:44 to 37:25

Explore the Treasury's report comparing the AI sector to the dot-com bubble and its risks.

“obtained a draft internal report from the Treasury Department that compares the current AI market to the dot-com bubble.”

Investment Strategies in AI

37:25 to 42:53

Discuss the importance of maintaining stable investments in AI companies amid market hype.

“Treasury is that AI will be a key driver of America's new golden age, which like, yeah, true.”

Investment Strategies in AI

42:57 to 43:09

Discuss the importance of maintaining stable investments in AI companies amid market hype.

“Carefully consider the investment material before investing, including objectives, risks, charges, and expenses.”

Radar Points: AI and Tech Trends

43:09 to 46:22

Discover the latest trends in AI, biotech, and aerospace industries.

“I've got three great radar points, Robert.”

Gen Z and the Side Hustle Economy

46:22 to 48:31

Explore the rising trend of side hustles among Gen Z and its implications.

“And Eli Lilly is just right at the forefront of that.”

Blue Origin's Funding and Future

48:31 to 50:46

Understand the significance of Blue Origin's recent fundraising efforts.

“I really like that call out on Blue Origin.”
Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:01This episode is brought to you by Google Chrome. You think you know a browser, but Gemini and Chrome, that's new. It can help you with practically anything on the web, like restoring a vintage motorcycle from a 50-page restoration block, or finally break down that long article you've had open for weeks. Gemini and Chrome is here for it. Ready to make anything online make sense? There's no place like Chrome. Check responses set up required, compatibility and availability varies 18+. When you need to build up your team to handle the growing chaos at work, use Indeed Sponsored Jobs. It gives your job post the boost it needs to be seen and helps reach people with the right skills, certifications and more.

0:38Spend less time searching and more time actually interviewing candidates who check all your boxes. Listeners of this show will get a$75 sponsored job credit at Indeed.com slash podcast. That's Indeed.com slash podcast. Terms and conditions apply. Need a hiring hero? This is a job for Indeed Sponsored Jobs. You are listening to The Rich Habits Radar, our Friday episode of The Rich Habits Podcast, where every Friday morning, we're coming at you with the biggest headlines impacting you and your money. This episode is brought to you by VCX, the public ticker for private tech. My name is Austin Hankwitz.

1:10I'm joined by my co-host, Robert Croak. And the three things sitting at the top of our Rich Habits Radar this week include Trump saying the Iran ceasefire is over. Yeah, that just happened. SK Hynix going public on Friday, and the U.S. Treasury warning of an AI bubble. Like, straight up U.S. Treasury. Really interesting. But before we talk about these three super important radar points, Miles Harrison, president and CEO of ConnectShoe, is joining us on the show. Our conversation is going to be about the intersection of artificial intelligence and biotechnology and how his company ConnectShoe is now operating inside of a massive tailwind created by the rise of GLP-1s.

1:50I mean, it's like buzzword after buzzword after buzzword. It's really cool. It's a great conversation. We filmed it actually a couple days ago here, so we're going to drop it into this episode before we get started because we're really, really excited about it, and y 'all are going to love it. So we'll see you back here in about 20 minutes. All right, let's jump to our conversation with Miles. All right, everyone, so before we jump to our radar points for this week's episode, we've got a guest joining us that I've been really excited about. And I want to set this up because it ties directly into something that we've been watching all year long.

2:21Back in January, Eli Lilly and NVIDIA announced a billion-dollar AI-powered drug discovery lab. Lilly, biologists working now side-by-side with NVIDIA AI engineers, over a thousand Blackwell Ultra GPUs, the whole thing. Then in May, Google's isomorphic labs, their AlphaFold spinoff, raised$2.1 billion in a Series B to start pushing AI design drug candidates into actual clinical trials. And then just this month, biotech mergers and acquisitions hit$106 billion year to date, already on pace to be the best year since before COVID. So a lot of big money is flowing and flooding into now this intersection of artificial intelligence and biotech.

3:09So today we're sitting down with someone who's building at that exact intersection. Miles Harrison, the CEO of Connect U Sciences, ticker CNXU, which just started trading on the NASDAQ last month. And for all of you joining today, Miles is not new to this game. This guy ran Galderma's entire North American business. Maybe the Cetaphil brand rings a bell to you guys, scaling it from$1.2 billion to over $2.1 billion in revenue. He also co-founded an aesthetics company, built it from scratch, and sold it in another eight-figure exit in about four years. He also sits on the board of Castle Biosciences, which is another NASDAQ-listed company.

3:49Now he's leading ConnectSue, which is developing a patented collagen-based tissue regeneration platform. And we are going to get into all of that. What does it mean? Why AI is about to blow the doors off of biotech? And why GLP-1s might be creating an entirely new market for what his company is building? Miles, I'm super excited and welcome to the show. Thank you very much. Thanks for having me. So let's get right into it. This has been a big topic for Austin and I for quite some time. And I'm excited to learn more for my own health reasons in this episode. So let's talk about artificial intelligence.

4:23It's disrupting basically every part of our lives at this point. We talk about it on this show pretty much every single week. But biotech seems like it might be the next major benefactor of this technology. When you look at where AI is headed, why do you think biotech could end up being the biggest AI winner in the coming years? Great question. So biology has always been hardest, you know, in terms of finding data. And for the first time, I believe, we have a tool that can actually keep up with it. So I spend my career, as you mentioned, Galderma and previously Novartis, and I've been on the commercial side.

5:00And always that you find that biology moves a little slower than, you know, the capital wants it to. So when you're watching a compound, a promising compound sort of play out, it can take three to four years. Drug discovery can take 10 to 12 years. You can iterate in the lab before anybody can actually tell you that it really works. And the way that science, you know, the predictability of the science. So AI changes that slope. You can search chemical and biological space. You can flag formulations. You can also look at, you know, how to shorten the distance between your hypothesis and the real answer.

5:35So software disruption was really about distribution and getting a good idea to people faster. And biotech disruption is more about discovery itself moving faster. So that's a bigger prize. And healthcare touches every single person on the planet. So in a way that no app ever will. And our founder, Dr. Claudia Chavez, she's a co-founder, actually, is your chief scientific officer. She's been living inside this extracellular matrix science that we've been working on for over a decade. And she put it well to me recently where biology generates more data than we've even been able to interpret. But AI is the first technology that closes that gap.

6:13So I think that's where we will win speed and getting around all of that data, which is quite significant for biology. I love that breakdown, Miles. And I think it's really important because it really ties into my question here, which is, you know, the health care innovation cycles. I would argue how it has been traditionally is someone has research on a drug or some sort of hypothesis, and then they spend years or decades trying to really hone in on the best deliveries. They do the different types of trials, like all these other different things. But now with artificial intelligence, I got a hunch that healthcare innovation cycles are getting compressed.

6:52Things that used to take a decade or more now might take three, four, five years. Are you seeing that yourself in the data? Well, research and design side, yes, I think meaningfully, right? So I think that you can go much faster. But on the clinical and the regulatory side, no, and it shouldn't because, you know, AI can compress how fast you can analyze literature or optimize a formulation or design an experiment or interpret, you know, imaging data. And we've seen those cycles shrink. We've seen populations in clinical trials reduced because there's more data and you can act faster. But there's a part of the business that AI cannot and should not compress, and that's the clinical validation.

7:29So patient safety operates on biological time and not computational time. So, you know, you can't simulate your way to a 510k clearance, for example, or a pre-marketing authorization, a PMA approval, and you wouldn't want to. So what we see is that in some parts of the business, you know, you can speed up the first bit, but certainly for safety and efficacy and how products work in the body, I don't think you can speed that up because, you know, it's biology at work. So the honest answer is that, you know, the funnel maybe gets faster, but the finish line doesn't move dramatically just because the funnel did.

8:05That's a great perspective to share. I appreciate that. Yeah, I've seen, you know, I want to say I was listening to a podcast the other day and someone was talking about how like, I don't know much about DNA and genomics and like all the fun stuff. But they were talking about, you know, leaps and bounds and strides that have been made because of artificial intelligence just in the last couple of years here. But I completely agree. You know, that's a computational clock that is getting compressed from a research perspective. But the trials, the biological, how it actually affects the body definitely should not rush that one.

8:35Well, I'm excited about all of it because for me, it's, you know, I want to live forever. And if we can figure all this out with AI and modern technology and medicines and reverse aging or slow aging down, I am all for it. But, Miles, we've seen Eli Lilly become one of the most valuable companies on the planet, largely off the back of the GLP-1s and innovation in that weight loss and metabolic health space. Could the next trillion dollar companies come from AI-powered healthcare rather than software? Is Lilly an early example of what that looks like? Break that down for our listeners. Yeah, I think it's not just possible.

9:12I think it's already underway. I think that Lilly is a fair, there's the early adopter here and they bet big, right? And they have big pockets, so they can bet big and good for them. Lilly didn't become one of the most valuable healthcare companies through a software multiple. It's really got there with a biological problem at scale that people have worked on for years. And it touches an enormous percentage of the population. You know, in 2030, GLP-1 is going to be worth$200 billion, McKinsey recommends. $200 billion prescription market. I mean, that's phenomenal. So there's a, you know, I think the last 25 years of trillion dollar companies came from software because software was the technology that could scale a single idea to, you know, billions of dollars.

9:56and healthcare can't do that. Biology doesn't scale like code. So AI is starting to close that gap and it's helping to scale the discovery process itself. So if we can speed up the discovery process, then literally we can touch more humans and more potential solving for humankind. Then that's a huge upside, I think, where AI lets healthcare innovation move at a fraction of software speed, but the ceiling is enormous. You can arguably build bigger, more addressable problems from AI. Something that we are big proponents here, Miles, on the show is finding the picks and shovels of big secular growth trends, right?

10:35Who's really going to benefit from a$200 billion, you know, market with GLP-1s? And you actually wrote a piece earlier this year about why the GLP-1 boom now demands a new aesthetic playbook. There's millions of people who are losing weight rapidly on these drugs and experiencing real tissue depletion. So my question is, are GLP-1s creating now an entirely new healthcare market that maybe didn't exist five or 10 years ago? Absolutely. If you think about weight loss and if you think about taking a GLP-1, we're having so many amazing results, you know, for people who are using it for weight loss and they're seeing massive gains in terms of how their weight is disproportionately just dropping off every day.

11:22So what are they seeing though? They're seeing weight being lost around their stomach or in the middle where they want to lose the weight, but they're also seeing weight being lost in other areas, areas that maybe they don't want weight loss, fat pads in the face, for example, some body contouring areas, areas where they probably wouldn't want to lose weight. So GLP-1s were initially built to treat metabolic disease. And what they're actually doing is creating this, you know, massive downstream patient population at scale. And, you know, this volume loss gives loose skin and the match doesn't really match what people expected.

11:54It's not a niche, but, you know, now one in eight U.S. adults is on a GLP-1. So we talked about that 200 billion, one in eight on a GLP-1 and 63 % are going out into an aesthetic practice or a plastic surgeon or dermatologist looking for a solution. These are new patients. So this is a big upside, I think, for plastic surgeons and for injectors who can help them on that journey. So I've lived through aesthetics. It's been an amazing market. Genuinely, we've had some great tools for 20 plus years, but not really new tools, right? So I would say that they're just different components of the same thing.

12:33So a lot of good renovation and a lot of good marketing and access certainly has been dramatic, you know, with private equity coming in and building out big chains. So access has been there. Pricing has been competitive with new companies. But, you know, HA, hyaluronic acid injectables, are really just fillers, right? They just they're volumizers and biostimulators are there as a foreign body object. They just inject and they cause a foreign body object response. And that's inflammation. And that inflammation helps create, you know, the collagen that you've lost and the elastin that you've lost over aging.

13:08So when this happens rapidly, you need something to come in, but you need something to last. So the tools today were never actually designed for the GLP-1 patient. You can argue, you can modify, but it's not really solving the purpose. They were added for adding volume and therefore a structural framework, but not for the structural framework that's collapsed. So you have this big demand, a real gap, and what I believe is extracellular matrix, so a tissue regeneration, an approach where you can bring cells, signals, and structure through an injectable, which we have, really is the next category.

13:45This is a Botox-like moment. Botox, you know, back in the day, wasn't for, as a neuromodulator for freezing the forehead and for the glabella lines. Botox was actually for strabismus as an eye product. And that's a$9 billion category. I think regenerative tissue opportunities like ECM-based approaches we have will be the next category, and they will work the same way that biostimulators did back in the day and neuromodulators once did. I don't think GLPs have created a new pharmaceutical market. They've created a patient population that the next generation of aesthetic medicine is going to be built around.

14:23I want our listeners to bring in a notepad and start writing down numbers here. So you said that one in eight American adults are on a GLP-1. And then of that one in eight American adults on a GLP-1, you said 63 % of them or 60 % of them or so are going and actively looking for, you know, different ways to make their appearances look better now that they've lost weight, which is tens of millions of Americans. like if you actually do the numbers on that. And so it's your hunch that of these tens of millions of Americans, those people are also going to go want to look and find a solution for tissue regeneration and really fortify their body and the weight in the good places versus like the fat that they originally like tried to lose, right?

15:05So like that's your hunch is that these tens of millions of people that are actively every year looking for and spending money on ways to make their bodies look better after they've lost weight are also going to say, light bulb moment, I need to go do some tissue regeneration stuff as well. Well, they're going to say, I need to go and get a volumizer. And then they're going to go to a practice and they can have something that lasts six to nine months. Or they can have something that is clean and natural beauty. It's your own tissue being regenerative. Our product is a hydrogel and collagen-based product.

15:32So when you inject that, it adds volume. It adds volume just like an HA will. But then it doesn't go away. What happens is cells and signals. And that structure provides an environment for tissue regeneration. so you maintain the volume. So you're not losing volume over time. You're not going to have to re-inject in that same area. That's our hunch. That's what we're working on our preclinical work right now. I just want to be really clear. When you say tissue, like when I think tissue, I think like muscle tissue or like, you know, organ tissue and stuff like that. Is that the type of tissue that people are losing whenever they're on these GLP-1s?

16:06And that's the type of tissue that they need to get back without gaining a proportional amount of fat across their bodies? Is that what you're saying? Tissue regeneration is where we're coming from in terms of wound care and burns. That's where the 11 publications, 12 years of history of design of this product was to conform to an irregular wound, a dehesant wound, a surgical wound, a tunneling wound, all these very tough wounds. So that's where we're coming from. So we're not talking about organ regeneration here. So we're just talking about a volumizer right now. We can use certainly in aesthetics.

16:39It's tissue agnostic. Tissue meaning, you know, dental, periodontitis meaning dermal, subcutaneous. And why do we know that? We've already shown on our website, you can see in the preclinical work that it's tissue agnostic. Where we inject, we're seeing cell reorganization. We're seeing some vascularization. That's veins, right? And we're seeing adipose tissue being laid down, certainly in the subcutaneous. So this is phenomenal. So you're regenerating your own tissue. That's providing the volume. That maintains the volume. And that's natural and clean beauty as far as I'm concerned. And I want to click back on this even one more time.

17:15So I'm sure of this because this is exciting for me of what I'm trying to do to, you know, stay youthful and all that. You talk about volumizer. So I assume this can be utilized in the face to restore volume as well, right? Because you mentioned Botox and all these other things, right? Sure. So we've done rheology and we are, you know, we're on par with one of the top brands in the market. So it's important, you know, we have fine lines, the nasal labial folds that come down here from the side of the mouth is the crow's feet, you know, up here. So, yes, in your facial areas, but there's volume loss here, the fat tissues, the fat pads here.

17:50You need to get some rounding, jawline, right? So this product will work across those, but also across for the body, right? So if you think about other areas like cellulite, right? So you've got the dimpling. You could smooth that. and certainly any other pockets. So whether it's aesthetics or correctional or GLP-1 impacted, you know, sagging skin. Absolutely, this is where you can inject. I love it, Miles. This is exactly right in my wheelhouse of what I'm trying to learn too. So this is gonna be great for our audience because this is such a big sector. So I wanna talk through this a little bit more technical for my next question.

18:27You have the CXU platform, a liquid extracellular matrix scaffold with applications across wound care, aesthetics, dental, even breast reconstruction with your breast program at Wake Forest. Is Connection building a product, a platform, or both? And what is the difference for our listeners? Sure. So we're building a platform. So your listeners should be informed about the fact that this is one formula that can go across multiple areas. So in essence, it's a platform. What you should understand is that to get this product to market the fastest way and the way that we've been focused for many years is through wound care.

19:06So we will do a 510k, which is an FDA route to get a class two medical device on the market. So the 510k is the regulatory route. Once that goes in, then that informs us on everything else that we want to do within the platform. It informs us from a manufacturing scaler, informs us from a chemical composition informs us from the bench to commercial. So what we're able to do then is use that as we get into other markets. But at the same time, as we get an approval, the fastest way to get an approval is a predicate. We'll use our own predicate then to get into the other markets using our predicate, which will be in wound care.

19:47That's the thinking that we have right now, as I said. Got it. I guess, you know, wrapping things up here, what does the next five years of ConnectsU look like. You guys just listed on the NASDAQ. Congratulations. That's so cool. You've got this week four's partnership, you know, 510K submission plan for windcare like you were just alluding to. Like, where is this company headed perhaps in the next four, five, six years? It's called by the end of the decade. It's 2030. What's ConnectsU working on? Well, I think we will be talking about GLP-1 patients and the benefits that they're going to be seeing with this portfolio of this product.

20:19I think we're going to be talking about the fact that there are not going to be the need for breast implants, but there could be the need for resorbable breasts, a natural resorbable breast that instead of having silicone, you can have a product that is fully resorbable. I mean, that's remarkable. And I think that, you know, longevity is playing a lot of roles in every conversation that people have. And longevity is really around regeneration. So I think the technology that we're bringing fits squarely into that, whether that's in dentistry, in veterinary, in 3D bioprinting, whether it's in breasts, you know, designing a breast, a resorbable breast, or whether that's injectable for Mohs surgery.

20:58It goes right across so many verticals. So I think regenerative medicine is here to stay. I think we're going to see a lot more competition coming, which is great for patients, certainly. And I think that, yeah, this, the people no longer want to mask something or cover something in wound care. They want it to actually regenerate and the tissue to get better. And I think we can bring something that will really, really help those who suffer from that. This is awesome stuff. I just, I get so excited. Robert, literally, you know, we've had conversations on the side because I know you've been, you've been really dialing your health over the last, let's call it like 12 to 18 months.

21:34Yeah. And we've had conversations on the side where you've like, listen, Austin, like all the best doctors I've talked to say, if you can just live for another five, seven, 10 years, we're going to have so much technology now with biotech that living longer and being healthier is going to be so much easier than it is today in 2026 or even 10 years ago. And, you know, 2016, like it's going to be just so much better. And talking with people like Miles here who are on the front, just building this stuff and doing their best, like it's so fascinating to me. And so Miles, thanks again so much for just cluing me in on this because, you know, you hear a lot about AI and biotech and GLP one and Reddit, True Tide this or whatever's going on and sexy and fun on Instagram at the time.

22:14But this is real tech that's, that's really moving and grooving in the right direction. And I'm just glad that I'm alive to witness it. Yeah. And I've been giddy about this interview for days now, just because I am living through it right now. I'm trying to get my A1C in order. I'm trying to like figure out how to get the volume back in my face and keep my skin looking good, but it's crazy to think with all of what you're building, Miles, and what's happening in the biotech and medical field that I might be able to live another 50 years of healthy life, 40, 50 years of healthy life pretty easily.

22:50That excites me because I want to keep doing this with Austin for many decades to come here in the Rich Habits Podcast, and it's guests like you that make it so exciting to share all this information with our audience. Well, Robert, I think, you know, you're one of those who is getting hold of their own health and working it out right which is fantastic the other thing you can do is you know where you're going to go with your health so you can there's a prognostic way right rather than the diagnostic way so you can start to inform yourself what can i do to help myself going forward now rather than to support the eventual maybe loss of loose skin you know so get to it sooner earlier you know and that's what we see well that's what we've seen in aesthetics over years.

23:31And that's what we're going to see across many of these other verticals that we're talking about. Wow. Thanks again for joining us, Miles. Really appreciate it, man. Thank you. Appreciate your time. Welcome back, everyone. What an awesome conversation with Miles. Austin, let's dig into our radar points. Starting off today, is the Iran ceasefire actually over? On Wednesday morning, President Trump stood at the NATO summit in Ankara, Turkey, and said, for me, I think it's over. Talking about the 60-day ceasefire with Iran, the deal struck on June 17th that was supposed to suspend hostiles and let diplomats negotiate the free passage through the state of Hormuz.

24:07The deal is now apparently dead. Trump told reporters, we're going to hit them hard again tonight, and I'll give them little warning. We're going to hit them hard again tonight. So Austin, I just want this to be over. Yeah, same here, man. Well, let's talk through the chain of events. Iran's Revolutionary Guard Corps attacked three commercial tankers in the Strait of Hormuz earlier this week. Then the U.S. retaliated on Tuesday night by striking over 80 Iranian targets, CENTCOM confirmed, and then Iran escalated things even further, launching ballistic missiles and drones at Bahrain and Kuwait, two U.S.

Read the full transcript

24:39Gulf allies who had nothing to do with the original dispute. And now Kuwait confirmed that they intercepted two ballistic missiles and 13 drones, and Bahrain confirmed interceptions of its own. Now Iran's parliament released a statement saying the U.S. must, and I quote, recognize the new Iranian order in the Strait of Hormuz. That is a sovereignty claim over a waterway that carries 20 percent of the world's oil supply every single day. This is nuts and I'm over it. I have to wrap it up. I can't do this anymore. But more specifically, Robert, what does this mean for everyone listening right now and their money?

25:15Yeah, it means you're right. We have to get this over with. This is a geopolitical risk repricing event. For months, oil has been falling back towards pre-war levels, and the market was pricing in a soft landing where energy costs weren't a variable anymore, and that assumption might now be wrong. If crude oil stays above that$80 a barrel for any sustained period, it feeds directly into inflation expectations. And if inflation expectations rise, the Fed has less room to pause, let alone cut rates. Remember, we just got the June jobs report last week and only 57 ,000 jobs were added. This is the biggest miss of the year.

25:52And investors were starting to believe the labor market was cooling enough for a rate relief. And this oil shock throws that entire thesis into question. And I know this seems like a lot of gloom and doom, but Austin, walk us through it. Yeah. So when you think about your portfolio, and we've kind of played this energy game all year long inside the Rich Habits Network, but energy stocks are the obvious near term hedge if you're someone that's like freaking out about volatility. XLE, Exxon, ConocoPhillips, Chevron, they all benefit from a higher crude oil per barrel price. But the bigger risk is what does this do to consumer spending, corporate margins, rate sensitive sectors like real estate and small caps?

26:32You know, Robert, we just hosted inside the Rich Habits Network, our weekly live stream that takes place every Tuesday. And I had shared a chart with everyone that had illustrated how oil right now, as of, I guess, like a week ago, was one of the most shorted names with 40 % of managed money, like money managers being bearish on oil and shorting it, the third highest reading in 15 years. So now what I said is I said, wait a second, when everyone, right, 40%, right, that's, that's a lot, third highest reading in 15 years, when a lot of people have a consensus view of something being bearish and bad, that usually marks a local bottom for that specific name.

27:07That said, I don't know how high oil might go from here, but if you kept a couple oil names in your portfolio like we have this year, maybe it's a good hedge right now against market volatility. Yeah, great breakdown, Austin, because we all know the markets don't like uncertainty. And right now, every single day, it seems like there's volatility around all of these headlines. And this has been the biggest narrative we've faced with this around war and all the uncertainty around oil. Now let's jump to our second story today, Robert, which I think is an exciting one, which is the SK Hynix IPO taking place this Friday.

27:41So on Friday, a company that most Americans have never heard of is expected to begin trading on the NASDAQ under the ticker symbol SKHY. The company is SK Hynix, and the listing is set to raise$28 billion, making it one of the largest share offerings in modern history. For comparison, and I know SpaceX was massive, but let's talk about it for a second, right? Right. SpaceX IPO raised$85 billion. SK Hynix is going to be$28 billion. So, you know, about$50 billion short, but still pretty big if you ask me. Well, this leads to what we talked about a few weeks back leading into the SpaceX IPO of where is all of this liquidity going to come from?

28:21And this is a big IPO, even though we're looking at SpaceX just, you know, from a couple of weeks ago. And SK Hynix is a South Korean semiconductor company, and it is arguably one of the single most important suppliers in the entire AI supply chain. And I like that you alluded that most people don't even know what it is. It's kind of like reminds me of Taiwan Semiconductor. They're one of the backbones of AI, but because they're not in the United States, they're just not followed as much. And they make these high bandwidth memory HBM. And these are the specialized chips that sit on top of NVIDIA's GPUs and make AI training possible.

28:54Without SK Hynix's memory chips, NVIDIA's H200 and B200 processors are just looked at as expensive paperweights. I love that headline, and I'm going to say it, but yes, that's interesting to see. But without this memory, the processing units inside the NVIDIA chips simply cannot access or transfer data at the speeds required for modern AI and these LLM workloads. So Robert alluded to SK Hynix makes these high bandwidth memory specialized chips and the company actually controls over 50 % of the global high bandwidth memory market HBM. They've secured 70 % of NVIDIA's next generation HBM4 orders.

29:36So think Blackwell, Vera Rubin, like NVIDIA needs SK Hynix and their HBMs to ensure that the chips that NVIDIA is building in these stacks for large language models and AI training is actually useful. And their head of sales said on their most recent earnings call that client requests for HBM chip supplies over the next three years already far exceeds our production capacity. capacity. SK Hynix is already trading on the Korean Stock Exchange. They hit a$1 trillion market cap on May 27th. Now they're hanging around a trillion, a trillion three, depending on the day, but it is definitely something I'm keeping an eye on, Robert.

30:12Yeah, this could be a really good IPO for everyone listening and following along because I think it is going to sneak under the radar a little bit because everyone's talking about Anthropic, OpenAI, SpaceX and all that. And this is a really good one for everyone to watch. And when looking at it, Q1 2026 revenue came in at about$35.5 billion and profits surged fivefold year over year. The stock is up over 200 % year to date on the Korean exchange and Goldman Sachs, UBS, and every major bank has rated them as a dominant player in AI memory through at least 2027. And the U.S. listing isn't a traditional IPO.

30:50It's an ADR offering. What does that mean? It's an American depository receipt, meaning SK Hynix is issuing new shares that will trade on the NASDAQ while also remaining listed in Seoul, Korea. Trading is expected to begin Friday, July 10th, so keep an eye on it. Yeah, South Korean stock market's been on an absolute tear and an absolute roller coaster at the same time. The KOSPI is up a ton this year, driven almost entirely by SK Hynix and Samsung. Korean retail investors have been pouring money into these 2 and 3x leveraged ETFs on chip stocks, and regulators are beginning to be worried if this has turned into some sort of, you know, AI mania taking place over there.

31:29Yeah, I feel like AI mania is taking place just about everywhere where there's development in this sector. So SK Hynix wants access to institutional capital that doesn't panic sell on overnight KOSPI swings. We've seen that happen a lot. And they want to be valued more like NVIDIA on fundamentals, not leveraged ETF flows. And they also want U.S. passive fund inclusion. If SKHY gets added to major U.S. indices, the same automatic buying machine that just added SpaceX would start flowing into SK Hynix. Austin, that was a lot. What does this mean for you and your money? Well, right now, NVIDIA gets all the headlines and all the excitement.

32:10But the companies building the actual memory, the actual chips that make AI physically possible, have been trading at a fraction of NVIDIA's multiples over the years. partly because they were stuck on foreign exchanges that American institutions couldn't easily access. So when SK Hynix starts trading on the NASDAQ, American fund managers, ETFs, retail investors, all the above, will be able to buy one of the most critical AI memory suppliers as easily as they can buy NVIDIA or AMD. Even if they eventually get added to the NASDAQ 100, that's hundreds of billions of dollars of index tracking pools and funds that start automatically buying this stock.

32:47Now what's interesting though, and I saw a chart on X about this, is that we are in a memory shortage. So I want to make sure we're on the same page here. Samsung and SK Hynix have been able to quadruple their profits year over year because they were able to raise prices on their products by 30, 50, 80 percent to their customers and their customers had to pay those higher prices because of the shortage. They were the only ones selling memory. But in the back half of 26 and the first half of 27, I've seen rumblings by banks online, specifically on X, talking about how we'll be in a surplus. So I don't know if that same pricing power is as durable as investors might think.

33:26So if you are looking into an SK Hynix IPO, or you're looking into Micron and looking into these names to add it to your portfolio today, just be weary as to how important the surplus versus contraction and restriction around their products and how that could impact the durability of their pricing. Yeah, I think that's a great point for everyone to understand. Is AI overhyped at this point? Is there a chance for this bubble that we're hearing about any of those things? But I think for me, for people's portfolio, the question should be simple. Do you want exposure to the AI trade at the infrastructure layer or the application layer?

34:03SK Hynix is as infrastructure as it gets. With 50 % of the HBM market share, 70 % of NVIDIA's next-gen orders, and demand exceeding production capacity for the next three years. The AI trade is definitely globalizing, and the NASDAQ is becoming the World Stock Exchange, and every major AI company on Earth wants to list here because that's where the capital is. It certainly is. And NASDAQ, if you're listening, I'd love to come check you out. We've been in the New York Stock Exchange a dozen times now. Would love to go check out the NASDAQ. Email us at richhabitspodcast at gmail.com. All right, Robert, our final story, the U.S.

34:41Treasury warning us about an AI bubble. So the NOTUS, which is a nonpartisan news outlet, obtained a draft internal report from the Treasury Department that compares the current AI market to the dot-com bubble. Career Treasury analysts wrote a report for Secretary Scott Besant, Fed Chair Kevin Walsh, and federal financial regulators warning that AI firms are now more deeply entrenched in the U.S. economy than their dot-com predecessors. And if the bubble pops, the damage would be systemic. Here's what the analysts found. The AI sector is increasingly concentrated within a small number of firms.

35:16It's heavily reliant on private market financing as well. It's massively invested in physical infrastructure data centers that only pay off if growth targets are met. Supply chain disruptions, geopolitical tensions, electricity bottlenecks, and utility shortfalls could all stall this momentum. We've been talking about this for a very, very long time, finding those picks and shovels within those sectors. And if AI companies can't monetize their products fast enough, the effects would ripple through the big banks, the hedge funds, private credit markets, chip manufacturers, cloud providers, and even utilities, the entire financial ecosystem.

35:52Now, this part stood out to me, Robert. So the analysts that wrote this report noted that fewer retail investors are backing AI than backed the dot-com stocks of the late 90s. Thinking about on the surface, okay, that just means that less retail investors might get torched if things go bad. True, maybe, but it could also mean that the AI trade now is dominated by institutional investors, right? They've had to raise this money from someone, and if retail's not buying, the pensions, the endowments, the hedge funds, the banks, those people are giving them money. So if AI and growth AI and all this stuff starts to, you know, stumble, those losses hit institutions that the rest of the economy now depends on.

36:30The analyst wrote that a sustained AI downturn would have a greater impact on institutional investors fundamental to economic stability than the dot-com crash did on retail investors. Yeah, two weeks ago, June 25th, Treasury Secretary Besant stood in New York and praised the hyperscalers for spending$750 billion on AI build-out this year. He compared it favorably to the dot-com era and asked, could we do at least that? Can we do maybe more? At the G7 meeting, when other leaders raised concerns about AI safety and job losses, Besant told them, quote, the biggest risk to AI is China getting ahead of us.

37:06Now, the weird part, though, Robert, is while he's saying that his own analysts sitting in his own building are writing the report that we're talking about right now, saying the biggest risk is the bubble popping. Treasury Department spokesperson dismissed the report as unvetted and not representation of the agency's policies and views. And they said the official position of the secretary in the U.S. Treasury is that AI will be a key driver of America's new golden age, which like, yeah, true. That's great. But also like really interesting to see kind of how this like back and forth is going. And just on July 7th, the Bank of England released its own financial stability report warning that an AI crash should cause a 2.2 % drop in UK GDP and plunge Britain into a recession.

37:46And Governor Andrew Bailey flagged cyber vulnerabilities, high leverage in AI sectors and correlated investor behavior as systemic risks. Senator Elizabeth Warren has proposed a bill requiring financial firms to disclose their AI exposure to the treasury and for the agency to report how the financial system would be affected by this AI downturn that they're talking about. Sounds to me like a lot of scare tactics and mumbo jumbo and people are just doing their jobs of like, let's think of complete downside, the worst part of this. But what's your take, Robert? What does this mean for you and your money?

38:23It's a tough one because we see all the CapEx spending. We see all of the advancements in AI. There's so much build out and infrastructure happening in the United States. But let's be clear what this is and what it isn't. This is not a prediction that AI is going to crash. The treasury analysts themselves said AI companies are more mature, more profitable, and have healthier balance sheets than dot-com era firms. I think, Austin, about a year ago, we did a whole big thing about this because back in the dot-com era, I lived through it. There just wasn't the revenue. There was a lot of hype and hyperbole around these companies, but there just wasn't the revenue and profits that we see today.

39:00But here's what it is. It's the first time the U.S. government's own financial analysts have formally documented the systemic risks of the AI trade. Yeah, no, it definitely is. And I think, you know, if I'm someone listening right now and I'm like, oh, my gosh, is the secretary telling me that the AI bubble's here and we're all going to get cooked and torched and it's over? Like, no, not at all. Like, I think a lot of this is just noise. And as someone who owns the S &P and the NASDAQ and a ton of NVIDIA and AMD and Micron, like I'm just ride the wave, baby. Like obviously the entire earth is being rebuilt right now with AI in mind.

39:34And NVIDIA is going to be a$10 trillion company sometime in my life. AMD will be a$5 trillion company sometime in my life as that continues. So four major hyperscalers spending hundreds of billions of dollars in CapEx. That money's got to flow to something. It's flowing to NVIDIA, to the SK Hynix, the data center REITs, the utilities, construction firms. Like that's GDP growth if you like it or not. If you own the S &P 500, you're already massively exposed to AI through the Mag 7. The question isn't whether is AI real. It's obviously real. The question is whether the hundreds of billions of dollars that the Magnificent 7 is spending on capital expenditures is going to be sustained if revenue growth does not keep pace.

40:13We've seen great revenue growth. Alphabet is a wonderful example of this. So I think it's great. Last thing I'll leave you here with, Robert, as we talk about this, NVIDIA right now at$194 a share, whatever it is today, is now trading below 20 times their 2026 earnings expectations and below 15 times their 2027 earnings expectations, which is the cheapest valuation since 2019 and the lowest valuation multiple of the AI boom. literally when i was writing this with robert i was like oh i need to go buy more nvidia stock and i put 10 grand into nvidia at 194 now who knows where it's going to go in the short term i don't care but i'm thinking about the next three five seven ten years into the future hopefully a four and a half trillion dollar valuation nvidia bodes well for my portfolio in the future as obviously they're going to grow their earnings so much over the coming years nvidia is still the ai platform layer across GPUs, networking, software, robotics, physical AI, people selling quality stocks out of their portfolio because they're bored and they're looking for the next, you know, micron or the next insert other company here that goes up by 200 % in three weeks.

41:23Like that is a terrible mistake. Do not make that mistake. Know what you own and dollar cost average into durable blue chip stocks and ETFs and index funds in your portfolio. I love that so much because how many times in the Rich Habits Network does someone DM us or ask us live, what's the next Palantir? What's the next NVIDIA? And now it's what's the next Micron? They're always chasing the next when we still love these companies. I think AMD is cheap. I think NVIDIA is cheap. I think Amazon is cheap. There's so much opportunity right in front of people, but they're always chasing the next thing.

41:57And I just love that you brought that up and broke that down for us. So Austin, before we go to our radar points, support from this show comes from VCX, the public ticker for private tech. For generations, American companies have moved the world forward through their ingenuity and determination. And for generations, everyday Americans could be a part of that journey through perhaps the greatest innovation of all, the U.S. stock market. It did not matter whether you were a factory worker in Detroit or a farmer in Omaha, anyone can own a piece of the great American companies. But now that's changed.

42:27Today, our most innovated companies are staying private rather than going public. And the result is that everyday Americans are excluded from investing and getting left further and further behind while a select few reap all the benefits. Until now. Introducing VCX, the public ticker for private tech. VCX by Fundrise gives everyone the opportunity to invest in the next generation of innovation, including the companies leading the AI revolution, space exploration, defense tech, and so much more. So visit getvcx.com for more information. That's getvcx.com. Carefully consider the investment material before investing, including objectives, risks, charges, and expenses.

43:04This and other information can be found in the Funds Perspectus at GetVCX.com. This is a paid sponsorship. All right, Robert, let's now jump to our radar points for this episode. I've got three great radar points, Robert. I know you've got three as well, so I will kick us off. The first one being the UAE has now certified the world's first commercial vertiport, and Joby Air Taxis are definitely going to benefit from this. So the UAE just became the first country on Earth to certify a purpose-built commercial vertiport for electric air taxis like Joby. The facility, called VDX, sits next to Dubai's International Airport and was certified by the UAE's General Civil Aviation Authority for full commercial operations.

43:44operations. Joby Aviation has a six-year exclusive contract to operate air taxis out of Dubai using its S-4 aircraft, which carries about four passengers at a 200 mile per hour speed with zero emissions. I think that's awesome, and I hope to see more of these VertiPorts hopefully around the United States. My second point to talk about today is Eli Lilly's Red Hatru Tide results that I think are insanely interesting. So Eli Lilly's next generation obesity drug, Retta Trutide, Retta, that I'm sure a lot of you all have seen on Instagram and TikTok, just delivered their phase three results that make ZepBow look like a warmup.

44:25In the Triumph One trials, patients on the highest dose lost an average of 85 pounds over two years, which is a third of their body weight, matching outcomes that used to require gastric bypass surgery. It's the first drug in its class. Eli Lilly is expected to file for FDA approval by Q4 this year. Seven more phase three readouts are still coming in 2026. All lands as Medicare just started covering GLP-1s for obesity at$50 a month on July 1st. And a Gallup poll this week showed 11 % of Americans are now using GLP-1s. I own Eli Lilly stock. I would encourage you all to do your own research and perhaps nibble on the stock as well.

45:01My last point here, Robert, and this one's kind of dystopian and weird, but like I'm actually looking forward to it. The first full-length movie starring an AI-generated actress is coming sooner than you think. A full-length film called Misaligned is heading into production starring Tilly Norwood, an entirely AI-generated actress created by the AI studio Particle 6. It's built as a comedy drama set inside the Tillyverse, with traditional writers, editors, and directors working alongside some of these AI creators. Particle 6 claims using Norwood instead of human actors slashes production costs by 90%, which is exactly what SAG-AFTRA is afraid of.

45:41The Actors Union called it a threat that devalues human artistry and uses stolen performances to put actors out of work. This comes after Dreams of Violet, a 75-minute film made entirely with AI video generation, and no human actors became the first fully AI-generated movie accepted into a major film festival. That, to me, is going to be the start of a very interesting secular growth trend of AI-only actors, actresses, videos, movies. Like, figure out how to profit from that. That's not going away, in my opinion. Yeah, your radar points are fire today because I think about, like, we've been talking about GLP-1s and the picks and shovels and how to make money in that sector.

46:22And Eli Lilly is just right at the forefront of that. But then also, you think about Hollywood moving forward. You know, these actors that are used to getting 20, 30, 50 million dollars of film, I feel like they're going to be cooked and we might see a lot more of them in TV commercials coming soon. So we'll see more people that are A and B listers doing these insurance commercials sooner than we think. So let me just go through my radar points real quick, Austin. SpaceX is now included in the NASDAQ. They officially joined the NASDAQ 100 index on July 7th of this year, trading under the ticker symbol SPCX.

46:55the aerospace giant that everyone knows made its debut June 12, 2026 for their IPO and was fast tracks the index. We're keeping an eye on it. We think SpaceX is going to be a great long-term buy, but just not yet for me. I want to see that price come down a little bit more. Now here's my favorite one today. 43 % of Gen Zers claim that they need a side hustle to survive. Surveys indicate that anywhere from 48 to 57 % of Gen Z actually maintain active side gigs with these ventures accounting for up to 57 % of their total income, which is just a crazy stat to me. So for many, the wages from their primary nine to five job are just no longer sufficient to keep up with the rising cost of living.

47:38I see this a lot with my younger employees and we see these headlines a lot, but I was shocked that 57 % of their total income is coming from the side gigs, not their primary job. And my last radar point today is Jeff Bezos' Blue Origin is raising$10 billion at$130 billion pre-money valuation, according to NYT Dealbook, making the first time in the company's 26-year history that Bezos has taken outside funding. Until now, Bezos has personally bankrolled the entire operation. And this is something we need to keep an eye on because this is very, very important after the SpaceX IPO. And it's also interesting because Austin and I have been talking for a long time about Rocket Lab and AST Space Mobile valuations and the stocks and what they bring to the table in this space race that's going on right now.

48:29So we'll keep an eye on those for the future. I really like that call out on Blue Origin. I mean, I'm not saying that they're going to become the next SpaceX or anything like that, but$130 billion valuation and Rocket Lab at$50 billion. And they have a very similar business model. It's like, is Rocket Lab undervalued right now? Like, I don't know. I think that's interesting. So good call outs, Robert. Appreciate everyone hanging out with us on this week's episode of the Rich Habits Radar. Be sure to go check out ConnectsU and all the fun things that they've got going on. More about that in the links in the show notes below.

48:59And don't forget about the seven-day free trial taking place inside the Rich Habits Radar. I talked about oil being a shorted name right now by money managers. We talked about that on this episode, but we talked about it for this episode inside our weekly live streams. Like we talk about so much incredible information. It's a seven-day free trial. So join, get a live stream completely for free. See if you like it. If you don't, that's fine. No problem. But if you do like it, you also get invited to invest alongside Robert and myself. And we are investing in the coolest pre-IPO companies. Thanks, everyone.

49:32And we'll see you tomorrow for our Q &A episode.

49:58Hey, it's Ryan Reynolds here for Mint Mobile. Now, I was looking for fun ways to tell you that Mint's offer of unlimited premium wireless for$15 a month is back. So I thought it would be fun if we made$15 bills. But it turns out that's very illegal. So there goes my big idea for the commercial. Give it a try at mintmobile.com slash switch. Up-round payment of$45 for three months, $90 for six months, or$180 for 12-month plan required. $15 per month equivalent. Taxes and fees extra. Initial plan term only. Greater than 50 gigabytes may slow when network is busy. See terms. Athletic Brewing Company crafts award-winning non-alcoholic beers for those who want to be part of every round.

50:36With over 185 flavor awards, They're exceptional NA beers that fit your lifestyle and any social occasion. Summer's full of good times and athletic fits right in. Go to athleticbrewing.com to have brews delivered to your door or find them at a bar, restaurant, or store near you. Near Beer. Athletic Brewing Company. Fit for all times.

From the publisher

Friday on a Thursday!

We're joined by Miles Harrison, CEO of Conexeu Sciences (Nasdaq: CNXU), to discuss the intersection of AI and bioscience + how GLP-1s are carving out a new market for them.

Click here to learn more!

---

🚀 Invest alongside Robert and Austin inside the Rich Habits Network, ⁠⁠click here!⁠⁠

---

🤖 VCX: the public ticker for private tech -- ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠click here or visit https://getvcx.com/ to learn more! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

---

📸 Join us on Friday, July 10 at 12p ET for our AI Agents webinar with Public!

⁠⁠⁠https://www.crowdcast.io/c/aiagents⁠⁠⁠

We're thrilled they're workshopping agents with us, and can't wait to learn from Stephen Sikes.

⁠⁠⁠CLICK HERE!⁠⁠⁠

---

⁠⁠⁠⁠🏆 Wall Street Favorites⁠⁠⁠⁠⁠⁠⁠⁠ is LIVE! ⁠⁠⁠⁠⁠⁠⁠⁠Click here⁠⁠⁠⁠⁠⁠⁠⁠ to see what Wall Street is buying before everyone else.

---

🧠 Ready to build your own investable index using AI? Generated Assets on Public makes it easy.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Click here to try Generated Assets!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

---

🚀 Join 900+ other podcast listeners inside of the Rich Habits Network and invest alongside Robert and Austin, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠click here!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

---

⚡️ Sign up for the Rich Habits Newsletter and never miss a market-moving headline again, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠click here!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

---

⭐ Download our FREE Financial Planner –⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠click here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

⭐ Download our FREE Budgeting Template –⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠click here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

⭐ Earn 3.8% on your savings with a High-Yield Cash Account –⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠click here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

⭐ Trade stocks, options, music royalties and crypto on Public –⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠click here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

---

👤 Explore everything Austin does –⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠click here ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

👤 Explore everything Robert does –⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠click here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

❓ Ask us questions for our Q&A episodes – @richhabitspodcast on Instagram

📬 Inquire about working together – christian@witz.vc

---

Disclosure: This content is sponsored by NEOS Investments. The creator is compensated by NEOS to discuss NEOS ETFs. This content is for informational purposes only, and is not personalized investment, tax, or legal advice, and does not constitute an offer to buy or sell any security. Investing involves risk, including possible loss of principal. Before investing, carefully review the NEOS ETFs prospectus at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠neosfunds.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

More from Rich Habits Podcast

All 396 episodes
AI & Bioscience w/ Miles Harrison (CEO of Conexeu), SK Hynix IPO & Blue Origin FundraiseRich Habits Podcast · 49 min
Listen in VO